logo

BIOCON vs THEMISMED: Stock Comparison

BIOCON vs THEMIS MEDICAREUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

BIOCON is the larger company by market capitalisation. BIOCON shows a higher ROE, a higher ROCE and a higher net margin, while THEMIS MEDICARE shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BIOCON leads 5; THEMISMED leads 6 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BIOCONTHEMISMED

Valuation lens

What price are you paying?

Market CapContext only
₹53,739 Cr
₹857 Cr
P/E RatioTHEMISMED has the lower reading
98.43x
23.09x ✓
P/B RatioBIOCON has the lower reading
1.57x ✓
2.32x
EPSTHEMISMED has the higher reading
₹0.87
₹2.67 ✓
Book ValueContext only
₹224.71
₹43.28
Dividend YieldTHEMISMED has the higher reading
0.15%
0.52% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
BIOCON is the larger company
₹53,739 Cr vs ₹857 Cr
P/E Ratio
THEMISMED has a lower P/E
23.09x vs 98.43x
P/B Ratio
BIOCON has a lower P/B
1.57x vs 2.32x
EPS
THEMISMED has higher earnings per share
₹2.67 vs ₹0.87
Dividend Yield
THEMISMED has a higher dividend yield
0.52% vs 0.15%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs 2.3%
EPS Growth (TTM YoY)
THEMISMED has faster EPS growth
0% vs -72.5%
ROE
BIOCON has a higher ROE
1.01% vs -4.71%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONTHEMISMED
Live Price₹330.3₹94.59
Day Change-1.4%-1.36%
Volume21.36 L48,840
52-Week High₹447.15₹140.6
52-Week Low₹330.75₹64.95
Distance from 52W High-26.13%-32.72%

Valuation

MetricBIOCONTHEMISMED
Market Cap₹53,739 Cr₹857 Cr
P/E Ratio98.43x23.09x
P/B Ratio1.57x2.32x
EPS₹0.87₹2.67
Book Value₹224.71₹43.28
Dividend Yield0.15%0.52%

Growth

MetricBIOCONTHEMISMED
Revenue Growth (TTM YoY)2.3%6.7%
EPS Growth (TTM YoY)-72.5%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricBIOCONTHEMISMED
ROE1.01%-4.71%
ROCE2.35%-0.63%
Net Margin2.29%0.33%
Operating Margin8.5%-0.79%
Debt to Equity0.4x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONTHEMISMED
Promoter Holding29.73%▼ 0.17 pp57.5%
FII Holding8.14%▲ 0.62 pp0.01%▼ 0.1 pp
DII Holding23.38%▼ 0.69 pp0.01%
Public Holding23.75%▲ 0.34 pp32.87%▲ 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOCON and THEMIS MEDICARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.